Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[15-O]-H2O PET Imaging for Coronary Artery Disease (RAPID-WATER-FLOW)
NCT05134012Phase 3Completed
- Sponsor
- MedTrace Pharma
- Start
- May 2022
- Primary completion
- Oct 2026
- Modality
- Positron Emission Tomography Imaging
- Countries
- 6
01
Overview
A Phase 3 trial of 15O-water in coronary artery disease (CAD), sponsored by MedTrace Pharma. Started May 2022; status: completed.
02
Drugs
15O-water
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05134012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134012.